Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial
根据 TOP2A 方案，对 HER2 阳性乳腺癌患者进行新辅助蒽环类药物化疗（5-FEC 方案）或不含蒽环类药物的化疗（多西他赛/卡铂方案）联合曲妥珠单抗和帕妥珠单抗治疗：一项多中心、开放标签、非随机 II 期试验
期刊:Breast Cancer Research and Treatment
影响因子:3
doi:10.1007/s10549-024-07285-y
Ginzac, Angeline; Molnar, Ioana; Durando, Xavier; Motte Rouge, Thibault De La; Petit, Thierry; D'hondt, Véronique; Campone, Mario; Bonichon-Lamichhane, Nathalie; Venat Bouvet, Laurence; Levy, Christelle; Augereau, Paule; Pistilli, Barbara; Arsene, Olivier; Jouannaud, Christelle; Nguyen, Suzanne; Cayre, Anne; Tixier, Lucie; Mahier Ait Oukhatar, Céline; Nabholtz, Jean-Marc; Penault-Llorca, Frédérique; Mouret-Reynier, Marie-Ange
